Crucell NV (Leiden, The Netherlands), has  announced that it will receive up to $5 million from the Aeras Global TB  Vaccine Foundation (Rockville, MD), to support the development of its AdVac-  and PER.C6-based tuberculosis vaccine candidate.

  Aeras and Crucell began jointly  developing this vaccine candidate, called AERAS-402, in 2004 using Crucell’s  AdVac

vaccine technology and PER.C6 manufacturing technology. A  Phase 1 clinical trial launched in October 2006 in the US indicated  that the vaccine candidate is safe in healthy adults. A second study, currently  in progress in healthy adults in South Africa, appears to be showing  safety, tolerability, and immunogenicity of AERAS-402. 

  The main parameters under  examination in the St. Louis  study will be the immunogenicity and safety of BCG prime followed by two  AERAS-402 boost doses administered at three to six month intervals after BCG in  healthy adults. 

News

Crucell NV (Leiden, The Netherlands), has announced that it will receive up to $5 million from the Aeras Global TB Vaccine Foundation (Rockville, MD), to support the development of its AdVac- and PER.C6-based tuberculosis vaccine candidate.